Mumbai, Aug 14: The unaudited financial statements for Q1FY27 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 120 countries across the globe.
Key Consolidated Financial Highlights:
|
Particulars |
Q1 FY27 |
Q1 FY26 |
|
Revenues (in Rs Cr) |
189.75 |
145.07 |
|
EBITDA (in Rs Cr) |
47.46 |
51.70 |
|
EBITDA Margin |
25.0% |
35.6% |
|
PAT (in RsCr) |
24.04 |
34.79 |
|
PAT Margin |
12.7% |
24.0% |
|
Quarterly EPS (in Rs) |
2.99 |
4.32 |
Key Highlights for Q1 FY27:
In Q1 FY27, Supriya Lifescience Ltd. witnessed a 30.8 % year-over-year growth in Revenue to Rs 189.75 crore compared to Rs 145.07 crore in Q1 FY26.
EBITDA for Q1 FY27 stood at Rs 47.46 crore, with an EBITDA margin of 25.0%, as against Rs 51.70 crore in Q1 FY26 with a margin of 35.6%.
The Profit After Tax (PAT) for Q1 FY27 was Rs 24.04 crore, compared to Rs 34.79 crore in Q1 FY26. The PAT Margin stood at 12.7% in Q1 FY27 versus 24.0% in Q1 FY26.
The Anesthetic segment continued to be the largest therapeutic contributor in Q1 FY27, accounting for 48% of revenue, compared to 53% in Q1 FY26. Vitamins contributed 17% of revenue in Q1 FY27, compared to 11% in Q1 FY26.
Asia became the largest market in Q1 FY27, contributing 39% of revenue, compared to 32% in Q1 FY26; while Europe’s contribution came at 35% in Q1 FY27. LATAM contributed 20%, while North America and other markets contributed 3% each.
Export contribution stood at 81% of Q1 FY27 revenue, reflecting the Company’s continued focus on global markets and diversified geographic presence.
During the quarter, the Company continued to build momentum across its product portfolio. The Cardiovascular product launched in Q3 FY26 began contributing revenue in Q4 FY26, with momentum strengthening for future scale-up. The ADHD product witnessed strong demand from LATAM and Europe and is now scaling up. The Liquid Anesthetic product has been commercialised, with steady monthly supplies underway.
The Company is also advancing its FY27 product pipeline, with plans for approximately two launches each in Anesthetic and ADHD, aimed at deepening the product pipeline and supporting future growth.
Capacity utilisation stood at 70% in Q1 FY27, compared to 74% in FY26 and 70% in FY25. The Company continues to expand its manufacturing footprint, with a total reactor capacity of 932 KLPD across its manufacturing blocks.
The Ambernath facility has commissioned its finished dosage manufacturing capabilities, with tablets, capsules, liquids, nasal, inhalation and injections among the dosage forms covered. Validation and registration batches are underway for dossier submissions.
The Company continues to strengthen its R&D capabilities, with 68+ scientists focused primarily on API and formulation process development. The Company has also started two R&D centres at Ambernath and Lote, while continuing efforts to add 3–4 products annually.
Dr. Satish Wagh, Executive Chairman and Whole-Time Director, Supriya Lifescience Ltd., commenting on the results, said, “Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets. Our focus remains on expanding our product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments. With a strong export-oriented business, continued investments in capacity and innovation, and a growing pipeline across Anesthetic and ADHD, we remain focused on building sustainable long-term growth.”